Unlock AI-driven, actionable R&D insights for your next breakthrough.

Creatine Phosphate Microbial Limits: Comprehensive Analysis Of Quality Control, Enzymatic Production, And Regulatory Standards

NOV 17, 202652 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Creatine Phosphate microbial limits represent critical quality control parameters in pharmaceutical and nutraceutical manufacturing, encompassing both the enzymatic biosynthesis pathways involving microbial systems and the stringent microbiological purity specifications required for therapeutic-grade Creatine Phosphate products. Understanding microbial contamination thresholds, fermentation-based production constraints, and analytical detection methods is essential for ensuring product safety, efficacy, and regulatory compliance in clinical applications ranging from myocardial protection to sports nutrition.
Want to know more material grades? Try Patsnap Eureka Material.

Microbial Enzymatic Production Systems For Creatine Phosphate And Associated Contamination Risks

The microbial production of Creatine Phosphate via enzymatic catalysis has emerged as a green alternative to chemical synthesis, yet introduces specific microbiological quality challenges. Recombinant Escherichia coli strains such as BL21(DE3)-pET21a(+)-CPK have been engineered to express high-activity creatine kinase, achieving enzyme activities up to 30 U/g wet cell mass and crude lysate activities of approximately 6 U/mL 1. In this system, creatine (10 g/L) and adenosine triphosphate (ATP, 7.5 g/L) are converted to Creatine Phosphate in the presence of 65 mmol/L magnesium sulfate at pH 9.0 and 37°C over 3 hours, with optimal enzyme loading at 450 U/L 1. While this bioprocess offers mild reaction conditions and simplified downstream purification compared to multi-step chemical routes, the use of live microbial biomass or cell lysates necessitates rigorous control of residual viable cells, endotoxins, and enzymatic by-products.

Microbial contamination risks in fermentation-derived Creatine Phosphate arise from several sources:

  • Endotoxin carryover: Gram-negative hosts like E. coli release lipopolysaccharides (LPS) during cell lysis; endotoxin levels must remain below 0.5 EU/mg for parenteral formulations per USP <85> guidelines.
  • Residual host cell proteins (HCP): Incomplete removal of bacterial proteases or nucleases can compromise product stability and trigger immunogenic responses.
  • Adventitious agents: Cross-contamination during fermentation scale-up or inadequate sterilization of bioreactor components may introduce environmental bacteria, yeasts, or molds.

To mitigate these risks, manufacturers implement multi-barrier strategies including sterile filtration (0.22 μm), chromatographic polishing (anion exchange to remove nucleic acids and HCP), and validated viral inactivation steps (e.g., low-pH hold at pH 3.5 for 1 hour), even though bacterial fermentation does not inherently carry viral risk 1.

Creatinine-Metabolizing Microbial Enzymes: Implications For Creatine Phosphate Purity

Several microbial genera—Brevibacterium, Corynebacterium, Pseudomonas, and Arthrobacter—produce creatinine desiminase (creatinine iminohydrolase), which catalyzes the hydrolysis of creatinine to N-methylhydantoin and ammonia 2,6. Although these organisms are not typically employed in Creatine Phosphate synthesis, their enzymatic activities are relevant to quality control: residual creatinine (a cyclization product of creatine) in Creatine Phosphate raw materials can be degraded by contaminating microorganisms during storage or formulation, leading to ammonia accumulation and pH drift. Creatinine desiminase from Pseudomonas or Brevibacterium exhibits optimal activity at pH 7–8 and 30–37°C, conditions that overlap with typical pharmaceutical storage environments 2,6.

Analytical methods to detect such microbial enzyme activities include:

  • Ammonia release assays: Spectrophotometric detection of ammonia (Berthelot reaction) after incubating product samples with suspect microbial isolates.
  • N-methylhydantoin quantification: HPLC-UV at 210 nm to monitor creatinine breakdown products.
  • Microbial identification: 16S rRNA gene sequencing of isolates from failed sterility tests to assess enzymatic degradation potential.

Manufacturers must validate that total aerobic microbial count (TAMC) remains ≤10² CFU/g and total yeast and mold count (TYMC) ≤10¹ CFU/g per Ph. Eur. 2.6.12 for non-sterile solid dosage forms, or achieve sterility (zero CFU in 20 units tested) for injectable Creatine Phosphate per USP <71> 13.

Fermentation Process Parameters And Microbial Limit Control In Creatine Phosphate Biosynthesis

Optimized fermentation protocols for creatine kinase production directly influence downstream microbial burden. A two-phase fed-batch strategy has been reported for creatinine iminohydrolase (a related enzyme) production in aerobic soil microorganisms, which serves as a model for Creatine Phosphate enzyme fermentation 8,11:

Phase 1 (Batch growth on ammonia):

  • Initial medium: 18.2 g/L α-ketoglutaric acid, 10.6 g/L glucose, 10.9 g/L (NH₄)₂SO₄, 0.45 g/L creatinine, 10.0 g/L K₂HPO₄, 1.5 g/L MgSO₄·7H₂O, pH 7.05 11.
  • Temperature: 30–37°C; agitation: 200–800 rpm; aeration: 0.5–1.5 vvm.
  • Duration: Until ammonia depletion (indicated by dissolved oxygen spike), typically 10–15 hours.

Phase 2 (Nitrogen-limited fed-batch with creatinine induction):

  • Creatinine feed: 74 g/L solution added at 1.0–1.5 g/L/h to induce enzyme synthesis 8,11.
  • pH control: Automated addition of 373 g/L α-ketoglutaric acid solution to maintain pH 7.0–8.0, preventing acidification and supplying carbon without inhibitory substrate shock 8.
  • Endpoint: Enzyme activity plateau (typically 10–15 hours post-induction), with final titers of 6–10 U/mL crude lysate 1,8.

Critical microbial limit controls during fermentation include:

  • Aseptic inoculum transfer: Seed cultures grown on creatinine-supplemented agar slants (2% agar, 0.5% creatinine, 0.05% bromothymol blue indicator) are verified for purity by color shift to alkaline (blue) within 2–6 days, confirming creatinine-utilizing phenotype and absence of contaminants 3,4.
  • In-process bioburden monitoring: Samples withdrawn every 6–12 hours are plated on tryptic soy agar (TSA) and Sabouraud dextrose agar (SDA) to detect bacterial and fungal contamination; counts should remain below 10³ CFU/mL in non-sterile fermentation or zero in sterile processes.
  • Endotoxin tracking: Limulus amebocyte lysate (LAL) assay (USP <85>) performed on clarified broth; acceptable levels <1 EU/mL during fermentation to ensure downstream purification can achieve final specification.

Post-fermentation, cells are harvested by centrifugation (8,000 × g, 20 min, 4°C) and lysed via ultrasonication (20 kHz, 50% duty cycle, 10 min on ice) or high-pressure homogenization (1,000–1,500 bar, 3 passes) 3,18. The lysate is clarified by centrifugation (15,000 × g, 30 min) and subjected to sterile filtration (0.45 μm pre-filter, 0.22 μm final filter) to remove residual cells and reduce bioburden to <10 CFU/100 mL prior to chromatographic purification 3.

Analytical Methods For Detecting Microbial Contaminants And Related Impurities In Creatine Phosphate

High-performance liquid chromatography with evaporative light-scattering detection (HPLC-ELSD) has been validated for quantifying inorganic phosphate and organic impurities in disodium Creatine Phosphate, which is critical for assessing microbial phosphatase activity 13. Microbial alkaline phosphatases can hydrolyze Creatine Phosphate to creatine and inorganic phosphate, reducing potency and generating a degradation marker. The HPLC-ELSD method employs:

  • Column: Reversed-phase C₁₈ (250 mm × 4.6 mm, 5 μm).
  • Mobile phase: Gradient of 10 mM ammonium acetate (pH 6.5) and acetonitrile (0–30% ACN over 20 min).
  • Detection: ELSD at 40°C evaporator, 2.5 bar nitrogen pressure; sensitivity ~0.1% w/w for inorganic phosphate 13.
  • Validation: Linearity (r² >0.999), precision (RSD <2%), LOD 0.05 mg/mL, LOQ 0.15 mg/mL.

Complementary microbiological assays include:

  • Sterility testing (USP <71>): Direct inoculation of 10 mL product into 100 mL fluid thioglycollate medium (FTM) and soybean-casein digest medium (SCDM), incubated at 30–35°C and 20–25°C for 14 days; no turbidity indicates sterility.
  • Bacterial endotoxin test (USP <85>): Kinetic chromogenic LAL assay with sensitivity 0.005 EU/mL; Creatine Phosphate for injection must contain <0.5 EU/mg.
  • Microbial enumeration (Ph. Eur. 2.6.12): Membrane filtration of 10 g product dissolved in 100 mL sterile saline, filtered through 0.45 μm membrane, incubated on TSA (TAMC) and SDA (TYMC) at 30–35°C for 3–5 days; colony counts extrapolated to CFU/g.

For creatinine and creatine quantification (to assess microbial enzymatic degradation), enzymatic endpoint assays using purified creatinine amidohydrolase and creatine amidinohydrolase are employed 3,4,18. These enzymes, produced from Alcaligenes sp. or Penicillium sp., convert creatinine to creatine (K_m ~25 mM at pH 8.0, 37°C) and creatine to sarcosine + urea (K_m ~20 mM) 16,18. Coupled with urease and glutamate dehydrogenase, the released ammonia is quantified spectrophotometrically at 340 nm (NADH oxidation), enabling detection limits of 0.01 mM creatinine/creatine 2,6.

Regulatory Standards And Pharmacopoeial Limits For Microbial Contamination In Creatine Phosphate Products

Creatine Phosphate is marketed in multiple dosage forms—injectable solutions (e.g., 1 g/5 mL ampoules for IV infusion in acute myocardial infarction), oral tablets (enteric-coated to enhance absorption), and topical formulations—each with distinct microbial limit specifications 9.

Injectable Creatine Phosphate (Sterile Products)

  • Sterility: Must pass USP <71> test (zero growth in FTM and SCDM after 14 days).
  • Bacterial endotoxins: ≤0.5 EU/mg per USP <85> (for a 1 g dose, ≤500 EU total, well below the pyrogenic threshold of 5 EU/kg body weight).
  • Particulate matter: ≤6,000 particles ≥10 μm and ≤600 particles ≥25 μm per container (USP <788>).
  • Bioburden pre-sterilization: ≤10 CFU/100 mL to ensure validated terminal sterilization (e.g., autoclaving at 121°C for 15 min or sterile filtration) achieves sterility assurance level (SAL) of 10⁻⁶ 13.

Oral Solid Dosage Forms (Non-Sterile)

  • TAMC: ≤10³ CFU/g (Ph. Eur. 2.6.12, Category 2 for oral products).
  • TYMC: ≤10² CFU/g.
  • Absence of specified microorganisms: Escherichia coli, Salmonella spp., Staphylococcus aureus, Pseudomonas aeruginosa must be absent in 1 g or 10 g sample (depending on product category).
  • Bile-tolerant Gram-negative bacteria: ≤10² CFU/g (for products with high risk of enteric pathogen contamination).

Enteric-coated Creatine Phosphate formulations (designed to resist gastric acid and release in the intestine, thereby improving bioavailability) must additionally meet dissolution specifications (e.g., <10% release at pH 1.2 after 2 hours, >80% release at pH 6.8 after 1 hour post-acid stage) and demonstrate microbial stability over 24-month shelf life at 25°C/60% RH 9.

Regulatory Guidance On Microbial Enzymes In Excipients

When microbial-derived enzymes (e.g., creatine kinase) are used as processing aids, residual enzyme activity must be validated as inactive in the final product. ICH Q6B recommends:

  • Enzyme activity assay: Residual creatine kinase <0.01 U/mg Creatine Phosphate (below pharmacologically active threshold).
  • Host cell DNA: <10 ng/dose (per WHO TRS 978) to minimize oncogenic risk.
  • Host cell protein: <100 ppm (per EMA guideline on immunogenicity).

Manufacturers must provide a detailed description of the microbial strain (deposited in a recognized culture collection, e.g., ATCC, DSM), fermentation history, and genetic stability data (e.g., plasmid retention over 50 generations) in regulatory submissions (CTD Module 3.2.S.2.3) 1,7.

Microbial Degradation Pathways Of Creatine Phosphate And Stability Implications

Microbial contamination can accelerate Creatine Phosphate degradation through enzymatic and non-enzymatic pathways:

Enzymatic Hydrolysis By Microbial Phosphatases

Alkaline phosphatases from E. coli, Bacillus spp., and Pseudomonas spp. catalyze:

Creatine Phosphate + H₂O → Creatine + Inorganic Phosphate

Optimal activity occurs at pH 8–10 and 37°C, with K_m values of 0.1–1 mM for Creatine Phosphate 17. In contaminated solutions stored at room temperature, phosphate liberation can reach 5–10% per week, detectable by HPLC-ELSD as increased inorganic phosphate peak area 13.

Creatine Cyclization To Creatinine (Non-Enzymatic, Accelerated By Microbial Metabolites)

Creatine spontaneously cyclizes to creatinine at acidic pH (<6) and elevated temperature (>40°C):

Creatine

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
TIANJIN QIREN MEDICAL TECHNOLOGY CO. LTD.Green enzymatic biosynthesis of pharmaceutical-grade Creatine Phosphate for injectable formulations in acute myocardial infarction treatment and quality-controlled production requiring TAMC ≤10² CFU/g and endotoxin <0.5 EU/mg per regulatory standards.Enzymatic Creatine Phosphate Production SystemRecombinant E. coli BL21(DE3)-pET21a(+)-CPK achieves creatine kinase activity of 30 U/g wet cell mass and crude lysate activity of 6 U/mL, enabling mild reaction conditions (pH 9.0, 37°C, 3 hours) with simplified downstream purification and reduced impurities compared to multi-step chemical synthesis.
KYOWA HAKKO KOGYO CO. LTD.Analytical quality control for detecting microbial enzymatic degradation in Creatine Phosphate raw materials during storage, preventing ammonia accumulation and pH drift that compromise product stability in pharmaceutical manufacturing and sterility testing per USP <71>.Creatinine Desiminase Enzyme ProductionAerobic fermentation of Brevibacterium, Corynebacterium, Pseudomonas and Arthrobacter genera produces creatinine desiminase with optimal activity at pH 7-8 and 30-37°C, catalyzing creatinine hydrolysis to N-methylhydantoin and ammonia for rapid quantitative determination.
BOEHRINGER MANNHEIM G.M.B.H.Enzymatic endpoint assays for quantifying creatinine and creatine impurities in Creatine Phosphate products to assess microbial contamination and validate compliance with Ph. Eur. 2.6.12 microbial limits (TAMC ≤10³ CFU/g, TYMC ≤10² CFU/g) for non-sterile oral dosage forms.Creatinine/Creatine Amidohydrolase Enzyme SystemPurified creatinine amidohydrolase from Alcaligenes sp. and Penicillium sp. exhibits Km ~25 mM at pH 8.0, 37°C for creatinine-to-creatine conversion, coupled with creatine amidinohydrolase (Km ~20 mM) enabling spectrophotometric detection limits of 0.01 mM via NADH oxidation at 340 nm.
EASTMAN KODAK COMPANYIndustrial-scale production of urease-free creatinine iminohydrolase from aerobic soil microorganisms with validated bioburden control (<10³ CFU/mL in-process) and sterile filtration (0.22 μm) to meet ICH Q6B guidelines for residual enzyme activity <0.01 U/mg and host cell DNA <10 ng/dose in Creatine Phosphate manufacturing.Two-Phase Fed-Batch Creatinine Iminohydrolase Fermentation ProcessNitrogen-limited fed-batch fermentation with creatinine feed at 1.0-1.5 g/L/h and pH control via α-ketoglutaric acid (373 g/L solution) achieves enzyme titers of 6-10 U/mL crude lysate while preventing substrate inhibition and maintaining endotoxin <1 EU/mL for downstream purification to pharmaceutical specifications.
SHANGHAI HUATUO MEDICAL SCIENCE CO. LTD.Quality control of Creatine Phosphate disodium salt intermediates and final products to monitor microbial phosphatase contamination (from E. coli, Bacillus, Pseudomonas spp.) that accelerates degradation at 5-10% per week at room temperature, ensuring potency retention and compliance with injectable sterility requirements (zero CFU per USP <71>).HPLC-ELSD Impurity Detection Method for Disodium Creatine PhosphateReversed-phase C18 HPLC with evaporative light-scattering detection at 40°C achieves sensitivity of 0.1% w/w for inorganic phosphate (LOD 0.05 mg/mL, LOQ 0.15 mg/mL) with linearity r²>0.999 and precision RSD <2%, enabling detection of microbial alkaline phosphatase activity that hydrolyzes Creatine Phosphate to creatine and phosphate.
Reference
  • Method for producing phosphocreatine by microbial enzyme method
    PatentInactiveCN102808006A
    View detail
  • creatinine deimidase
    PatentInactiveSE7609154L
    View detail
  • Creatine amidohydrolase in the conversion of creatinine to creatine
    PatentInactiveUS3912588A
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png